Oncology In vivo CAR-T can solve the delivery problem – but solid tum... A new generation of in vivo CAR-T cell technologies promises to remove some of the biggest practical barriers to conventional cell therapy.
News AstraZeneca’s volrustomig hits Phase 3 setback in lung cance... In another blow to its late-stage pipeline, AstraZeneca has pulled the plug on a phase 3 trial of its lung cancer treatment volrustomig.
R&D On the power of T-cells, with Cedrik Britten Dr Cedrik Britten, chief medical officer at Immatics, discusses novel PRAME-directed T-cell immunotherapies.
R&D JP Morgan 2023 – Alexandre LeVert Editor-in-chief Jonah Comstock caught up with Alexandre LeVert, chairman, CEO, and co-founder of Osivax, on the sidelines of JP Morgan in San Francisco at the beginning of January of this year.&nbs
Events Partner Content 4th Annual Cell Engager Summit | May 24-26 | Boston, MA Learn from the pioneers of immunotherapy
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.